Literature DB >> 17317173

Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for sigma receptors.

Rong Xu1, John R Lever, Susan Z Lever.   

Abstract

5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2,3-dimethoxy-benzamide (1) is one of the most potent and selective sigma(2) receptor ligands reported to date. Previous structure-activity relationship studies of such tetrahydroisoquinolinyl benzamides have focused on the linker that connects the ring systems and the effects of benzamide ring substituents. The present study explores the effects of fusing methylene-, ethylene-, and propylenedioxy rings onto the tetrahydroisoquinoline in place of the two methoxy groups. These modifications decreased sigma(2) affinity by 8- to 12-fold, with no major differences noted with ring size. By contrast, the methylenedioxy analog showed a 10-fold greater sigma(1) affinity than 1, and progressively lower sigma(1) affinities were then noted with increasing ring size. We also opened the tetrahydroisoquinoline ring of 1 to study the effects of greater conformational fluidity on sigma receptor binding. The sigma(2) affinity of the open-ring compound decreased by 1700-fold, while sigma(1) affinity was not changed. Thus, a constrained tetrahydroisoquinoline ring system is key to the exceptional sigma(2) receptor binding affinity and selectivity of this active series.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317173      PMCID: PMC2659500          DOI: 10.1016/j.bmcl.2007.02.005

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

Review 1.  Sigma receptors: potential medications development target for anti-cocaine agents.

Authors:  Rae R Matsumoto; Yun Liu; Megan Lerner; Eric W Howard; Daniel J Brackett
Journal:  Eur J Pharmacol       Date:  2003-05-23       Impact factor: 4.432

2.  Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands.

Authors:  Robert H Mach; Yunsheng Huang; Rebekah A Freeman; Li Wu; Suwanna Vangveravong; Robert R Luedtke
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 3.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

Review 4.  Sigma receptors and cancer: possible involvement of ion channels.

Authors:  Ebru Aydar; Christopher P Palmer; Mustafa B A Djamgoz
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

5.  Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer.

Authors:  Amalia Azzariti; Nicola A Colabufo; Francesco Berardi; Letizia Porcelli; Mauro Niso; Grazia M Simone; Roberto Perrone; Angelo Paradiso
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

6.  [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe.

Authors:  Jinbin Xu; Zhude Tu; Lynne A Jones; Suwanna Vangveravong; Kenneth T Wheeler; Robert H Mach
Journal:  Eur J Pharmacol       Date:  2005-11-10       Impact factor: 4.432

Review 7.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines.

Authors:  Nicola Antonio Colabufo; Francesco Berardi; Marialessandra Contino; Mauro Niso; Carmen Abate; Roberto Perrone; Vincenzo Tortorella
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-31       Impact factor: 3.000

Review 9.  SR31747A: a peripheral sigma ligand with potent antitumor activities.

Authors:  Pierre Casellas; Sylvaine Galiegue; Bernard Bourrie; Jean-Bernard Ferrini; Omar Jbilo; Hubert Vidal
Journal:  Anticancer Drugs       Date:  2004-02       Impact factor: 2.248

10.  Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503.

Authors:  John R Lever; Jennifer L Gustafson; Rong Xu; Rachel L Allmon; Susan Z Lever
Journal:  Synapse       Date:  2006-05       Impact factor: 2.562

View more
  6 in total

1.  Effect of structural modification in the amine portion of substituted aminobutyl-benzamides as ligands for binding σ1 and σ2 receptors.

Authors:  Kuo-Hsien Fan; John R Lever; Susan Z Lever
Journal:  Bioorg Med Chem       Date:  2011-02-12       Impact factor: 3.641

2.  An unambiguous assay for the cloned human sigma1 receptor reveals high affinity interactions with dopamine D4 receptor selective compounds and a distinct structure-affinity relationship for butyrophenones.

Authors:  Ivan T Lee; Shiuhwei Chen; John A Schetz
Journal:  Eur J Pharmacol       Date:  2007-10-02       Impact factor: 4.432

Review 3.  The σ2 receptor: a novel protein for the imaging and treatment of cancer.

Authors:  Robert H Mach; Chenbo Zeng; William G Hawkins
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

Review 4.  Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity.

Authors:  Markos-Orestis Georgiadis; Olga Karoutzou; Angeliki-Sofia Foscolos; Ioannis Papanastasiou
Journal:  Molecules       Date:  2017-08-25       Impact factor: 4.411

5.  Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective.

Authors:  Antonino N Fallica; Valeria Pittalà; Maria N Modica; Loredana Salerno; Giuseppe Romeo; Agostino Marrazzo; Mohamed A Helal; Sebastiano Intagliata
Journal:  J Med Chem       Date:  2021-06-02       Impact factor: 7.446

6.  QSAR-Based Computational Approaches to Accelerate the Discovery of Sigma-2 Receptor (S2R) Ligands as Therapeutic Drugs.

Authors:  Yangxi Yu; Hiep Dong; Youyi Peng; William J Welsh
Journal:  Molecules       Date:  2021-08-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.